🇺🇸 FDA
Patent

US 9850542

Gene signature to predict homologous recombination (HR) deficient cancer

granted A61KA61K31/167A61K31/436

Quick answer

US patent 9850542 (Gene signature to predict homologous recombination (HR) deficient cancer) held by The Board of Regents of the University of Texas System expires Mon Dec 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Dec 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/167, A61K31/436, A61K31/502, A61K31/5377